Vasomotor Menopausal Symptoms (VMS) Treatment Market Report 2026

The vasomotor menopausal symptoms (vms) treatment market size has grown strongly in recent years. It will grow from $19.01 billion in 2025 to $20.16 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to increasing prevalence of menopausal symptoms, widespread use of hormone replacement therapy, growing clinical research on neurotransmitter-based treatments, expansion of women’s health services, improved access to specialty clinics.

The vasomotor menopausal symptoms (vms) treatment market size is expected to see strong growth in the next few years. It will grow to $26.48 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to rising demand for non-hormonal treatment alternatives, increasing awareness of menopause-related health management, growing investments in women’s health research, expansion of telemedicine-based treatment delivery, development of next-generation VMS therapeutics. Major trends in the forecast period include increasing development of non-hormonal therapies, growing adoption of personalized menopause treatment plans, rising use of digital health platforms for symptom management, expansion of combination drug therapies, enhanced focus on long-term safety profiles.

The government's initiatives for women's health in menopause are expected to propel the growth of the vasomotor menopausal symptom’s treatment market going forward. Government initiatives for menopausal health encompass funding for innovative studies on menopausal transition, illness prevention, and research related pharmacological, clinical, and epidemiological aspects. These efforts are part of broader women's health initiatives that address diverse concerns. For instance, in January 2023, according to the Government of New South Wales, an Australia-based government agency, the government initiated $40.3 million over four years (2022-2023 to 2025-2026) to build up to 16 new programs for women facing severe menopausal symptoms. Therefore, the government's initiatives for women's health in menopause are driving the growth of the vasomotor menopausal symptoms’ treatment market.

Major companies operating in the vasomotor menopausal symptoms treatment market are developing products such as Veozah and getting approvals to provide new treatment options and meet unmet medical needs for patients. The approval of new drugs for menopause provides improved efficacy and safety compared to existing treatments. For instance, in May 2023, Astellas Pharma Inc, a Japan-based pharmaceutical company, received approval for Veozah (fezolinetant) 45 mg once daily from the Food and Drug Administration (FDA), a US-based federal agency for the treatment of menopausal vasomotor symptoms (VMS), which range from mild to severe. It is the first nonhormonal neurokinin 3 (NK3) receptor antagonist to be authorized for treating menopausal-related VMS. It is a hormone-free option that blocks a pathway in the brain that helps regulate these symptoms. It provides an alternative treatment option for women experiencing these symptoms, particularly those who cannot or prefer not to use hormone therapy. The approval of Veozah highlights its potential as a new drug for managing menopausal symptoms.

In November 2023, Pharmavite LLC, a US-based nutrition and wellness company, acquired Bonafide Health for US $425 million. Through this acquisition, Pharmavite aimed to strengthen its women’s health offerings by integrating Bonafide’s clinically supported, hormone-free menopause products, including options to relieve vasomotor symptoms such as hot flashes and night sweats, as well as products for vaginal dryness and other menopause-related concerns. Bonafide Health LLC is a US-based women’s health brand specializing in science-backed, over-the-counter (non-prescription) products designed to address symptoms associated with estrogen decline.

Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical plc, Endo Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2025. The regions covered in the vasomotor menopausal symptoms (vms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vasomotor menopausal symptoms (vms) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the vasomotor menopausal symptoms treatment market by increasing costs of imported active pharmaceutical ingredients, formulation excipients, and specialized manufacturing equipment used in hormone and non-hormonal drug production. Pharmaceutical manufacturers and healthcare providers in North America and Europe are most affected due to dependence on global drug supply chains, while Asia-Pacific faces cost pressure on export-oriented pharmaceutical manufacturing. These tariffs are contributing to higher drug prices and supply delays. However, they are also supporting domestic drug manufacturing, regional API production, and increased investment in localized pharmaceutical supply chains.

The vasomotor menopausal symptoms (vms) treatment market research report is one of a series of new reports that provides vasomotor menopausal symptoms (vms) treatment market statistics, including vasomotor menopausal symptoms (vms) treatment industry global market size, regional shares, competitors with a vasomotor menopausal symptoms (vms) treatment market share, detailed vasomotor menopausal symptoms (vms) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the vasomotor menopausal symptoms (vms) treatment industry. This vasomotor menopausal symptoms (vms) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vasomotor menopausal symptoms (VMS) treatment refers to the medical interventions and therapies used to alleviate or manage the various symptoms associated with menopause. Women experience the symptoms of VMS during menopause, which include hot flashes and night sweats. The treatment works by balancing hormone levels in the body and altering neurotransmitters in the brain.

The main types of drugs in vasomotor menopausal symptoms (VMS) treatment are antidepressants, fluoxetine, paroxetine, sertraline, hormone therapy, anticonvulsants, phenytoin, phenobarbital and others. Antidepressants refer to a class of medications primarily used to treat depression and certain other mental health disorders. They are distributed in several ways, such as in hospital pharmacies, online pharmacies, retail pharmacies and others for various end-users such as hospitals, specialty clinics, homecare and others.

The vasomotor menopausal symptoms (VMS) treatment market consists of revenues earned by entities by providing services such as cognitive-behavioral therapy, acupuncture, lifestyle modifications, herbal and vitamin supplements and complementary and alternative therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The vasomotor menopausal symptoms (VMS) treatment market also includes sales of natural supplements, cooling products, vaginal estrogen products, stress-reduction products, sleep aids and dietary supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.